AllianceBernstein’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-150,459
| Closed | -$3.03M | – | 3368 |
|
|
2021
Q3 | $3.03M | Sell |
150,459
-35,398
| -19% | -$977K | ﹤0.01% | 1912 |
|
|
2021
Q2 | $6.94M | Buy |
185,857
+7,700
| +4% | +$236K | ﹤0.01% | 1427 |
|
|
2021
Q1 | $4.55M | Buy |
178,157
+35,398
| +25% | +$904K | ﹤0.01% | 1615 |
|
|
2020
Q4 | $3.15M | Hold |
142,759
| – | – | ﹤0.01% | 1732 |
|
|
2020
Q3 | $2.57M | Sell |
142,759
-27,891
| -16% | -$577K | ﹤0.01% | 1710 |
|
|
2020
Q2 | $4.33M | Buy |
170,650
+30,500
| +22% | +$657K | ﹤0.01% | 1408 |
|
|
2020
Q1 | $2.58M | Sell |
140,150
-2,500
| -2% | -$48.6K | ﹤0.01% | 1521 |
|
|
2019
Q4 | $3.14M | Buy |
142,650
+77,050
| +117% | +$1.55M | ﹤0.01% | 1698 |
|
|
2019
Q3 | $942K | Hold |
65,600
| – | – | ﹤0.01% | 2277 |
|
|
2019
Q2 | $1.03M | Buy |
65,600
+7,700
| +13% | +$105K | ﹤0.01% | 2299 |
|
|
2019
Q1 | $848K | Buy |
57,900
+19,400
| +50% | +$223K | ﹤0.01% | 2310 |
|
|
2018
Q4 | $412K | Buy |
38,500
+8,600
| +29% | +$113K | ﹤0.01% | 2565 |
|
|
2018
Q3 | $456K | Buy |
29,900
+17,300
| +137% | +$252K | ﹤0.01% | 2664 |
|
|
2018
Q2 | $154K | Buy |
+12,600
| New | +$158K | ﹤0.01% | 3013 |
|
|
2015
Q2 | – | Sell |
-4,100
| Closed | -$99K | – | 3347 |
|
|
2015
Q1 | $99K | Buy |
4,100
+2,800
| +215% | +$63K | ﹤0.01% | 3030 |
|
|
2014
Q4 | $21K | Sell |
1,300
-1,300
| -50% | -$15K | ﹤0.01% | 3226 |
|
|
2014
Q3 | $33K | Hold |
2,600
| – | – | ﹤0.01% | 3140 |
|
|
2014
Q2 | $59K | Buy |
+2,600
| New | +$47.1K | ﹤0.01% | 3091 |
|
Other funds holding DRNA
AllianceBernstein's DRNA Position: Q4 2021 in Review
AllianceBernstein sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 150,459 shares — an estimated $3.03M sold.
AllianceBernstein first reported a position in DRNA in Q2 2014 and held it in 18 quarters. The position peaked at $6.94M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.
- AllianceBernstein reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
- AllianceBernstein sold 150,459 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $3.03M.
- AllianceBernstein first reported a position in Dicerna Pharmaceuticals, Inc. in Q2 2014 and held it in 18 quarters.
- AllianceBernstein's Dicerna Pharmaceuticals, Inc. position peaked at $6.94M in Q2 2021.
- 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.
Based on AllianceBernstein's 13F filing for Q4 2021, filed 14 Feb 2022.